TY - JOUR
T1 - Individualized Treatment for Immune Thrombocytopenia
T2 - Predicting Bleeding Risk
AU - Neunert, Cindy E.
PY - 2013/1
Y1 - 2013/1
N2 - Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.
AB - Treatment of patients with immune thrombocytopenia (ITP) is often directed at increasing the platelet count and preventing significant hemorrhage even when there is minimal bleeding present. This approach, however, requires that a large number of patients receive prophylactic treatment to prevent major bleeding events. Identification of initial risk factors for development of severe bleeding would allow for more directed and personalized therapy. This review provides a summary of the current literature with the intent to explore various clinical and laboratory risk factors for severe bleeding including mucosal bleeding, platelet count, and aspects of platelet function.
UR - http://www.scopus.com/inward/record.url?scp=84877677053&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84877677053&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2013.03.009
DO - 10.1053/j.seminhematol.2013.03.009
M3 - Article
C2 - 23664518
AN - SCOPUS:84877677053
SN - 0037-1963
VL - 50
SP - S55-S57
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - SUPPL.1
ER -